Dr. Anish K. Ray
Claim this profileCook Children's Medical Center
Affiliated Hospitals
Cook Children's Medical Center
Cook Children's Healthcare System
Clinical Trials Anish K. Ray is currently running
Trametinib
for Histiocytosis
The purpose of this Phase II clinical trial is to establish the safety and effectiveness of trametinib, a targeted therapy, for the treatment of newly or recently diagnosed Langerhans Cell Histiocytosis (LCH) among pediatric patients.
Recruiting
1 award
Phase 2
5 criteria
Vinblastine/Prednisone vs. Cytarabine
for Histiocytosis
Langerhans Cell Histiocytosis (LCH) is a type of cancer that can damage tissue or cause lesions to form in one or more places in the body. Langerhans cell histiocytosis (LCH) is a cancer that begins in LCH cells (a type of dendritic cell which fights infection). Sometimes there are mutations (changes) in LCH cells as they form. These include mutations of the BRAF gene. These changes may make the LCH cells grow and multiply quickly. This causes LCH cells to build up in certain parts of the body, where they can damage tissue or form lesions. For most patients with LCH, standard-of-care vinblastine/prednisone are used as front-line therapy while cytarabine therapy has been used as therapy for patients who develop recurrence. No alternate treatment strategy has been developed for frontline therapy in LCH. The purpose of this research study is to compare previously used vinblastine/prednisone to single therapy with cytarabine for LCH. We will evaluate the utility of an imaging study called a positron emission tomography (PET) scan to more accurately assess areas of LCH involvement not otherwise seen in other imaging studies as well as response to therapy. We also want to identify if genetic and other biomarkers (special proteins in patient's blood and in patient's cancer) relate to the response of patients LCH to study treatment.
Recruiting
4 awards
Phase 3
3 criteria
More about Anish K. Ray
Clinical Trial Related
1 year of experience running clinical trials · Led 3 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Anish K. Ray has experience with
- Trametinib
- Elimusertib
- Cytarabine
- Prednisone
- Vinblastine
Breakdown of trials Anish K. Ray has run
Langerhans Cell Histiocytosis
Lymphoma
Ewing Sarcoma
Alveolar Rhabdomyosarcoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Anish K. Ray specialize in?
Anish K. Ray focuses on Langerhans Cell Histiocytosis and Lymphoma. In particular, much of their work with Langerhans Cell Histiocytosis has involved treating patients, or patients who are undergoing treatment.
Is Anish K. Ray currently recruiting for clinical trials?
Yes, Anish K. Ray is currently recruiting for 2 clinical trials in Fort Worth Texas. If you're interested in participating, you should apply.
Are there any treatments that Anish K. Ray has studied deeply?
Yes, Anish K. Ray has studied treatments such as Trametinib, Elimusertib, Cytarabine.
What is the best way to schedule an appointment with Anish K. Ray?
Apply for one of the trials that Anish K. Ray is conducting.
What is the office address of Anish K. Ray?
The office of Anish K. Ray is located at: Cook Children's Medical Center, Fort Worth, Texas 76104 United States. This is the address for their practice at the Cook Children's Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.